Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Neurocrine Sues Lupin, Teva to Block Copies of Ingrezza Drug

July 19, 2021, 3:37 PM

Neurocrine said Lupin’s and Teva’s proposed generic versions of the 40- and 80-milligram capsules of its flagship Ingrezza, used to treat tardive dyskinesia, infringe as many as 16 patents for the drug.

  • Neurocrine is seeking court orders blocking copies until the patents have expired, according to complaints filed Friday in federal court in Wilmington, Delaware
  • Tardive dyskinesia, a side effect of certain medications used to treat mental illness, may appear as repetitive involuntary movements of face, torso and other body parts
  • Neurocrine asserted 13 patents against both Teva and Lupin, and three additional patents against Lupin, complaints ...